Λίστα αντικειμένων
Venetoclax Gets Breakthrough-Therapy Designation for AML
At 12-month follow-up, the overall response rate was 44 percent (complete remission, n=4; complete remission without complete marrow recovery, n=4; resistant disease, n=8; death before evaluation, n=2).
FDA Approves Combination Daunorubicin and Cytarabine for High-Risk AML
The drug was approved based on results from a study of 309 patients with newly diagnosed t-AML or AML-MRC who were randomized to receive daunorubicin and cytarabine either in the fixed-combination formulation or as separate treatments. Patients who received CPX-351 had a longer median overall survival compared with those who received separate treatments (9.56 months vs. 5.95 months).